Literature DB >> 9972165

HIV topic update: protease inhibitor therapy and oral health care.

S R Porter1, C Scully.   

Abstract

Protease inhibitors have been a major advance in the management of HIV disease and have reduced the frequency and severity of many complications, including some oral lesions. They may also be of value in the management of occupational exposures to the virus. However, they may produce adverse effects including oral symptoms such as paraesthesia, taste disturbances and xerostomia, and may interact with a number of drugs used in oral health care. This article summarises the current situation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9972165     DOI: 10.1111/j.1601-0825.1998.tb00273.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  5 in total

Review 1.  The significance of oral health in HIV disease.

Authors:  I L Chapple; J Hamburger
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

2.  HIV protease inhibitors block oral epithelial cell DNA synthesis.

Authors:  Robert J Danaher; Chunmei Wang; Andrew T Roland; Charlotte S Kaetzel; Richard N Greenberg; Craig S Miller
Journal:  Arch Oral Biol       Date:  2009-12-24       Impact factor: 2.633

Review 3.  Oral complications of HIV disease.

Authors:  Jair C Leao; Camila M B Ribeiro; Alessandra A T Carvalho; Cristina Frezzini; Stephen Porter
Journal:  Clinics (Sao Paulo)       Date:  2009-05       Impact factor: 2.365

4.  Oral manifestations of human immunodeficiency virus in children: An institutional study at highly active antiretroviral therapy centre in India.

Authors:  Srinivas Rao Ponnam; Gautam Srivastava; Kotaih Theruru
Journal:  J Oral Maxillofac Pathol       Date:  2012-05

5.  Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence.

Authors:  Vanila F Palmeira; Lucimar F Kneipp; Sonia Rozental; Celuta S Alviano; André L S Santos
Journal:  PLoS One       Date:  2008-10-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.